Logo image of JAGX

JAGUAR HEALTH INC (JAGX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:JAGX - US47010C8881 - Common Stock

1.33 USD
+0.16 (+13.68%)
Last: 12/10/2025, 8:00:02 PM
1.3101 USD
-0.02 (-1.5%)
After Hours: 12/10/2025, 8:00:02 PM
Fundamental Rating

2

JAGX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of JAGX have multiple concerns. While showing a medium growth rate, JAGX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year JAGX has reported negative net income.
JAGX had a negative operating cash flow in the past year.
In the past 5 years JAGX always reported negative net income.
In the past 5 years JAGX always reported negative operating cash flow.
JAGX Yearly Net Income VS EBIT VS OCF VS FCFJAGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

JAGX has a Return On Assets of -84.21%. This is in the lower half of the industry: JAGX underperforms 76.44% of its industry peers.
JAGX's Return On Equity of -508.83% is on the low side compared to the rest of the industry. JAGX is outperformed by 80.63% of its industry peers.
Industry RankSector Rank
ROA -84.21%
ROE -508.83%
ROIC N/A
ROA(3y)-84.47%
ROA(5y)-88.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JAGX Yearly ROA, ROE, ROICJAGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

With an excellent Gross Margin value of 81.88%, JAGX belongs to the best of the industry, outperforming 85.34% of the companies in the same industry.
In the last couple of years the Gross Margin of JAGX has grown nicely.
JAGX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 81.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.72%
GM growth 5Y19.68%
JAGX Yearly Profit, Operating, Gross MarginsJAGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

1

2. Health

2.1 Basic Checks

JAGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
JAGX has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, JAGX has less shares outstanding
JAGX has a better debt/assets ratio than last year.
JAGX Yearly Shares OutstandingJAGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
JAGX Yearly Total Debt VS Total AssetsJAGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

JAGX has an Altman-Z score of -12.61. This is a bad value and indicates that JAGX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -12.61, JAGX is doing worse than 79.06% of the companies in the same industry.
JAGX has a Debt/Equity ratio of 1.34. This is a high value indicating a heavy dependency on external financing.
JAGX has a worse Debt to Equity ratio (1.34) than 76.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF N/A
Altman-Z -12.61
ROIC/WACCN/A
WACC2.12%
JAGX Yearly LT Debt VS Equity VS FCFJAGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

JAGX has a Current Ratio of 0.95. This is a bad value and indicates that JAGX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.95, JAGX is not doing good in the industry: 85.34% of the companies in the same industry are doing better.
A Quick Ratio of 0.59 indicates that JAGX may have some problems paying its short term obligations.
JAGX has a Quick ratio of 0.59. This is amonst the worse of the industry: JAGX underperforms 88.48% of its industry peers.
Industry RankSector Rank
Current Ratio 0.95
Quick Ratio 0.59
JAGX Yearly Current Assets VS Current LiabilitesJAGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

6

3. Growth

3.1 Past

JAGX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.66%.
The Revenue has grown by 19.75% in the past year. This is quite good.
Measured over the past years, JAGX shows a quite strong growth in Revenue. The Revenue has been growing by 15.14% on average per year.
EPS 1Y (TTM)-21.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.08%
Revenue 1Y (TTM)19.75%
Revenue growth 3Y39.19%
Revenue growth 5Y15.14%
Sales Q2Q%-0.8%

3.2 Future

Based on estimates for the next years, JAGX will show a very strong growth in Earnings Per Share. The EPS will grow by 40.54% on average per year.
JAGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 118.46% yearly.
EPS Next Y89.56%
EPS Next 2Y40.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year24.03%
Revenue Next 2Y26.98%
Revenue Next 3Y160.53%
Revenue Next 5Y118.46%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JAGX Yearly Revenue VS EstimatesJAGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
JAGX Yearly EPS VS EstimatesJAGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2019 2020 2021 2022 2023 2024 2025 2026 -200M -400M -600M -800M -1B

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

JAGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JAGX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JAGX Price Earnings VS Forward Price EarningsJAGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JAGX Per share dataJAGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

JAGX's earnings are expected to grow with 40.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.54%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

JAGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JAGUAR HEALTH INC

NASDAQ:JAGX (12/10/2025, 8:00:02 PM)

After market: 1.3101 -0.02 (-1.5%)

1.33

+0.16 (+13.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-18 2025-11-18/bmo
Earnings (Next)03-30 2026-03-30/amc
Inst Owners2.37%
Inst Owner Change596.43%
Ins Owners0.25%
Ins Owner Change0%
Market Cap5.45M
Revenue(TTM)11.69M
Net Income(TTM)-40.65M
Analysts85.71
Price Target16.32 (1127.07%)
Short Float %3.31%
Short Ratio0.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.02%
Min EPS beat(2)-41.08%
Max EPS beat(2)9.04%
EPS beat(4)3
Avg EPS beat(4)30.68%
Min EPS beat(4)-41.08%
Max EPS beat(4)98.2%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.44%
Min Revenue beat(2)-23.04%
Max Revenue beat(2)-11.83%
Revenue beat(4)1
Avg Revenue beat(4)-12.25%
Min Revenue beat(4)-23.04%
Max Revenue beat(4)8.52%
Revenue beat(8)2
Avg Revenue beat(8)-11.83%
Revenue beat(12)4
Avg Revenue beat(12)-6.94%
Revenue beat(16)5
Avg Revenue beat(16)-11.51%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.46
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-33.58
EYN/A
EPS(NY)-5.79
Fwd EYN/A
FCF(TTM)-6.8
FCFYN/A
OCF(TTM)-6.75
OCFYN/A
SpS2.88
BVpS1.95
TBVpS-2.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -84.21%
ROE -508.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 81.88%
FCFM N/A
ROA(3y)-84.47%
ROA(5y)-88.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.72%
GM growth 5Y19.68%
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.95
Quick Ratio 0.59
Altman-Z -12.61
F-Score4
WACC2.12%
ROIC/WACCN/A
Cap/Depr(3y)32.24%
Cap/Depr(5y)19.49%
Cap/Sales(3y)5.33%
Cap/Sales(5y)3.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.08%
EPS Next Y89.56%
EPS Next 2Y40.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)19.75%
Revenue growth 3Y39.19%
Revenue growth 5Y15.14%
Sales Q2Q%-0.8%
Revenue Next Year24.03%
Revenue Next 2Y26.98%
Revenue Next 3Y160.53%
Revenue Next 5Y118.46%
EBIT growth 1Y-4.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.49%
OCF growth 3YN/A
OCF growth 5YN/A

JAGUAR HEALTH INC / JAGX FAQ

What is the fundamental rating for JAGX stock?

ChartMill assigns a fundamental rating of 2 / 10 to JAGX.


Can you provide the valuation status for JAGUAR HEALTH INC?

ChartMill assigns a valuation rating of 1 / 10 to JAGUAR HEALTH INC (JAGX). This can be considered as Overvalued.


What is the profitability of JAGX stock?

JAGUAR HEALTH INC (JAGX) has a profitability rating of 1 / 10.


Can you provide the financial health for JAGX stock?

The financial health rating of JAGUAR HEALTH INC (JAGX) is 1 / 10.